Clinical Trial Update: Outpatient Epcoritamab as 2L in NTE R/R DLBCL [Phase 2]

View source ↗

Summary

Outpatient epcoritamab is being studied as second-line therapy for relapsed or refractory diffuse large B-cell lymphoma in a Phase 2 trial, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 2 | Status: RECRUITING